{
  "nodes": [
    {
      "id": 0,
      "name": "All Clinical Trials"
    },
    {
      "id": 1,
      "name": "Phase 1 (Safety)"
    },
    {
      "id": 2,
      "name": "Phase 2 (Efficacy)"
    },
    {
      "id": 3,
      "name": "Phase 3 (Large-Scale)"
    },
    {
      "id": 4,
      "name": "FDA APPROVAL \u2b50"
    },
    {
      "id": 5,
      "name": "Long-term Follow-up"
    }
  ],
  "links": [
    {
      "source": 0,
      "target": 1,
      "value": 399,
      "label": "399 trials enter Phase 1"
    },
    {
      "source": 1,
      "target": 2,
      "value": 175,
      "label": "175 advance to Phase 2"
    },
    {
      "source": 2,
      "target": 3,
      "value": 43,
      "label": "43 advance to Phase 3"
    },
    {
      "source": 3,
      "target": 4,
      "value": 1,
      "label": "1 FDA approval (Casgevy)"
    },
    {
      "source": 1,
      "target": 5,
      "value": 80,
      "label": "80 enter long-term follow-up"
    }
  ],
  "casgevy_path": {
    "trialName": "CTX001 (Casgevy)",
    "disease": "Sickle Cell Disease & Beta-Thalassemia",
    "approvalDate": "December 2023",
    "significance": "First CRISPR therapy approved by FDA",
    "path": [
      "Phase 1",
      "Phase 2",
      "Phase 3",
      "FDA APPROVAL \u2b50"
    ]
  },
  "statistics": {
    "total_trials": 707,
    "phase1": 399,
    "phase2": 175,
    "phase3": 43,
    "fda_approved": 1,
    "followup": 80,
    "progression_rates": {
      "phase1_to_phase2": 43.9,
      "phase2_to_phase3": 24.6,
      "phase3_to_approval": 2.3
    }
  }
}